{"transactions":[{"id":427997,"issuer":{"id":16217,"kind":"organization","name":"Mylan II B.V.","symbol":"MYL"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16218,"kind":"person","name":"Abbott Products","position":2,"cik":"0001650190","reported_name":"Abbott Products","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16219,"kind":"organization","name":"Abbott Investments Luxembourg S.A R.L.","position":3,"cik":"0001635614","reported_name":"Abbott Investments Luxembourg S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, nominal value Euro 0.01 per share","published_at":"2017-03-24T11:34:04.000Z","date":"2017-03-23","kind":"sale","acquired":false,"shares":44000000,"price":41.6,"value":1830400000.0,"ownership":{"direct":false,"nature":"By Subsidiaries"},"balance_after":25750000,"source":{"system":"sec-edgar","filing":"0001104659-17-019006","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465917019006/a4.xml","form_type":"4"}},{"id":452100,"issuer":{"id":16217,"kind":"organization","name":"Mylan II B.V.","symbol":"MYL"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16406,"kind":"organization","name":"Abbott Established Products Holdings Gibraltar Ltd","position":2,"cik":"0001635611","reported_name":"Abbott Established Products Holdings Gibraltar Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16219,"kind":"organization","name":"Abbott Investments Luxembourg S.A R.L.","position":3,"cik":"0001635614","reported_name":"Abbott Investments Luxembourg S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Option (Obligation to Sell)","published_at":"2015-04-09T20:44:36.000Z","date":"2015-04-07","kind":"other","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Subsidiaries"},"balance_after":0,"derivative":{"exercise_price":56.8912,"exercise_date":"2015-03-31","expiration_date":"2015-04-30","underlying":"Ordinary Shares","underlying_shares":5250000},"source":{"system":"sec-edgar","filing":"0001104659-15-026765","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465915026765/a4.xml","form_type":"4"}},{"id":452099,"issuer":{"id":16217,"kind":"organization","name":"Mylan II B.V.","symbol":"MYL"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16406,"kind":"organization","name":"Abbott Established Products Holdings Gibraltar Ltd","position":2,"cik":"0001635611","reported_name":"Abbott Established Products Holdings Gibraltar Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16219,"kind":"organization","name":"Abbott Investments Luxembourg S.A R.L.","position":3,"cik":"0001635614","reported_name":"Abbott Investments Luxembourg S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, nominal value Euro 0.01 per share","published_at":"2015-04-09T20:44:36.000Z","date":"2015-04-07","kind":"other","acquired":false,"shares":5250000,"price":56.8912,"value":298678800.0,"ownership":{"direct":false,"nature":"By Subsidiaries"},"balance_after":69750000,"source":{"system":"sec-edgar","filing":"0001104659-15-026765","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465915026765/a4.xml","form_type":"4"}},{"id":452427,"issuer":{"id":16217,"kind":"organization","name":"Mylan II B.V.","symbol":"MYL"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16412,"kind":"organization","name":"Laboratoires Fournier S.A.S.","position":2,"cik":"0001635767","reported_name":"Laboratoires Fournier S.A.S.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16406,"kind":"organization","name":"Abbott Established Products Holdings Gibraltar Ltd","position":3,"cik":"0001635611","reported_name":"Abbott Established Products Holdings Gibraltar Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16219,"kind":"organization","name":"Abbott Investments Luxembourg S.A R.L.","position":4,"cik":"0001635614","reported_name":"Abbott Investments Luxembourg S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Call Option (Obligation to Sell)","published_at":"2015-04-02T20:34:26.000Z","date":"2015-03-31","kind":"other","acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Subsidiaries"},"balance_after":1,"derivative":{"exercise_price":56.8912,"exercise_date":"2015-03-31","expiration_date":"2015-04-30","underlying":"Ordinary Shares","underlying_shares":5250000},"source":{"system":"sec-edgar","filing":"0001104659-15-025547","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465915025547/a4.xml","form_type":"4"}},{"id":452426,"issuer":{"id":16217,"kind":"organization","name":"Mylan II B.V.","symbol":"MYL"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16412,"kind":"organization","name":"Laboratoires Fournier S.A.S.","position":2,"cik":"0001635767","reported_name":"Laboratoires Fournier S.A.S.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16406,"kind":"organization","name":"Abbott Established Products Holdings Gibraltar Ltd","position":3,"cik":"0001635611","reported_name":"Abbott Established Products Holdings Gibraltar Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16219,"kind":"organization","name":"Abbott Investments Luxembourg S.A R.L.","position":4,"cik":"0001635614","reported_name":"Abbott Investments Luxembourg S.A R.L.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares, nominal value euro 0.01 per share","published_at":"2015-04-02T20:34:26.000Z","date":"2015-03-31","kind":"other","acquired":false,"shares":35000000,"price":56.8912,"value":1991192000.0,"ownership":{"direct":false,"nature":"By Subsidiaries"},"balance_after":75000000,"source":{"system":"sec-edgar","filing":"0001104659-15-025547","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465915025547/a4.xml","form_type":"4"}},{"id":189011,"issuer":{"id":2800,"kind":"organization","name":"AbbVie Inc."},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.01 par value","published_at":"2012-12-14T22:22:44.000Z","date":"2012-12-12","kind":"other","acquired":false,"shares":101,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The record date for the distribution by Abbott Laboratories (\"Abbott\") of all of its shares of AbbVie Inc. (\"AbbVie\") to the holders of Abbott common stock was December 12, 2012 at the close of business.  The distribution of the shares is scheduled to occur on January 1, 2013."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-12-017658","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911012017658/edgar.xml","form_type":"4"}},{"id":511859,"issuer":{"id":16931,"kind":"organization","name":"Trubion Pharmaceuticals, Inc","symbol":"TRBN"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2010-12-10T21:54:00.000Z","date":"2010-10-28","kind":"other","acquired":false,"shares":2243649,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. (\"Trubion Common Stock\").   On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. (\"Emergent\"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. (\"Trubion\"), Emergent completed its acquisition of Trubion (the \"Merger\"). (Continued in Footnote 2)"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive:  an amount in cash equal to $1.365;  0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. (\"Trubion Common Stock\").   On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. (\"Emergent\"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. (\"Trubion\"), Emergent completed its acquisition of Trubion (the \"Merger\"). (Continued in Footnote 2)"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive:  an amount in cash equal to $1.365;  0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 relates to shares of common stock, par value $0.001 of Trubion Pharmaceuticals, Inc. (\"Trubion Common Stock\").   On October 28, 2010, pursuant to an Agreement and Plan of Merger dated August 12, 2010, as amended, by and among Emergent BioSolutions Inc. (\"Emergent\"), 35406 LLC, a direct wholly-owned subsidiary of Emergent, 30333 Inc., an indirect wholly-owned subsidiary of Emergent and Trubion Pharmaceuticals, Inc. (\"Trubion\"), Emergent completed its acquisition of Trubion (the \"Merger\"). (Continued in Footnote 2)"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) As a result of the Merger each of the 2,243,649 shares of Trubion Common Stock owned by Abbott Laboratories outstanding immediately prior to the effective time of the Merger was canceled and converted into the right to receive:  an amount in cash equal to $1.365;  0.1641 of a share of common stock of Emergent; and one Contingent Value Right, which entitles the holder thereof to receive a pro rata portion of certain contingent payments following the achievement of future development milestones under certain of Trubion's collaboration agreements."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-10-062171","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465910062171/a4.xml","form_type":"4"}},{"id":519867,"issuer":{"id":16988,"kind":"organization","name":"FACET BIOTECH CORP","symbol":"FACT"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16989,"kind":"organization","name":"Amber Acquisition Inc.","position":2,"cik":"0001486751","reported_name":"Amber Acquisition Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2010-04-21T21:07:32.000Z","date":"2010-04-21","kind":"other","acquired":true,"shares":5980034,"price":27,"value":161460918.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Reflects all of the outstanding shares of Facet not tendered in the offer, which may be deemed to have been acquired by Abbott and the Purchaser pursuant to the consummation of the Merger.  At the effective time of the Merger, these Shares were cancelled and ceased to exist."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F6","text":"Prior to the Merger, Abbott held 1,000 shares of the common stock, no par value per share, of the Purchaser (the \"Purchaser Shares\"), which represented all of the issued and outstanding capital stock of the Purchaser.   At the effective time of the Merger, each Purchaser Share was converted into one share of common stock of Facet, as the surviving corporation of the Merger, and as a result Abbott acquired 100% of the equity interest of Facet."}],"balance_after":1000,"source":{"system":"sec-edgar","filing":"0001104659-10-021021","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465910021021/a4.xml","form_type":"4"}},{"id":519866,"issuer":{"id":16988,"kind":"organization","name":"FACET BIOTECH CORP","symbol":"FACT"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":16989,"kind":"organization","name":"Amber Acquisition Inc.","position":2,"cik":"0001486751","reported_name":"Amber Acquisition Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2010-04-21T21:07:32.000Z","date":"2010-04-20","kind":"purchase","acquired":true,"shares":62652055,"price":27,"value":1691605485.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This form is a joint filing by Abbott Laboratories (\"Abbott\") and Amber Acquisition Inc., a wholly-owned subsidiary of Abbott (the \"Purchaser\")."},{"field":"security","element":"securityTitle","label":"F2","text":"This Form 4 relates to shares of common stock, par value $0.01 per share (the \"Common Stock\"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated as of September 7, 2009, as amended by the amendments thereto dated as of December 15, 2009, December 16, 2009 and March 9, 2010, by and between Facet and Mellon Investor Services LLC  (together with the Common Stock, the \"Shares\"), of Facet."},{"field":"shares","element":"transactionShares","label":"F3","text":"Reflects Shares of Facet acquired by the Purchaser upon the exercise of the \"top-up\" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on March 23, 2010 by Abbott and the Purchaser (the \"Schedule TO\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Following the exercise of the \"top-up\" option, Facet was merged with and into the Purchaser with Facet surviving the merger as a wholly-owned subsidiary of Abbott pursuant to a \"short-form merger\" under Delaware law as described in the Schedule TO (the \"Merger\").  At the effective time of the Merger, these Shares were cancelled and ceased to exist."}],"balance_after":81909724,"source":{"system":"sec-edgar","filing":"0001104659-10-021021","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465910021021/a4.xml","form_type":"4"}},{"id":532595,"issuer":{"id":17075,"kind":"organization","name":"ABBOTT MEDICAL OPTICS INC","symbol":"EYE"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2009-02-28T01:36:38.000Z","date":"2009-02-26","kind":"purchase","acquired":true,"shares":44720768,"price":22,"value":983856896.0,"ownership":{"direct":false,"nature":"By wholly owned subsidiary"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 relates to shares of common stock, par value $0.01 per share (the \"AMO Common Stock\"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated June 24, 2002, by and between Advanced Medical Optics, Inc., a Delaware corporation (\"AMO\"), and Mellon Investor Services, LLC (together with the AMO Common Stock, the \"AMO Shares\"), of AMO."},{"field":"security","element":"securityTitle","label":"F2","text":"The AMO Shares that are the subject of this report were acquired by Rainforest Acquisition Inc., a Delaware corporation and a wholly-owned subsidiary of Abbott (the \"Purchaser\"), upon the exercise of the \"top-up\" option described in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on January 27, 2009 by Abbott and the Purchaser."},{"field":"security","element":"securityTitle","label":"F3","text":"The amount of AMO Shares set forth in Column 5 of Table I reflects a downward adjustment of 1,537 AMO Shares to the number of AMO Shares previously disclosed as being subject to guaranteed delivery procedures and includes 4,469,463 AMO Shares tendered in the tender offer that remain subject to guaranteed delivery procedures."}],"balance_after":103565445,"source":{"system":"sec-edgar","filing":"0001104659-09-013218","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465909013218/a4.xml","form_type":"4"}},{"id":532758,"issuer":{"id":17075,"kind":"organization","name":"ABBOTT MEDICAL OPTICS INC","symbol":"EYE"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":17076,"kind":"organization","name":"Rainforest Acquisition Inc.","position":2,"cik":"0001454341","reported_name":"Rainforest Acquisition Inc.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2009-02-25T21:28:55.000Z","date":"2009-02-25","kind":"purchase","acquired":true,"shares":56395914,"price":22,"value":1240710108.0,"ownership":{"direct":false,"nature":"By wholly owned subsidiary"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This form is a joint filing by Abbott Laboratories (\"Abbott\") and Rainforest Acquisition Inc., a wholly-owned subsidiary of Abbott (the \"Purchaser\"). This Form 4 relates to shares of common stock, par value $0.01 per share (the \"AMO Common Stock\"), and the associated preferred stock purchase rights issued in connection with the Rights Agreement, dated June 24, 2002, by and between Advanced Medical Optics, Inc., a Delaware corporation (\"AMO\"), and Mellon Investor Services, LLC (together with the AMO Common Stock, the \"AMO Shares\"), of AMO."},{"field":"security","element":"securityTitle","label":"F2","text":"The AMO Shares that are the subject of this report were acquired by the Purchaser upon the expiration of the Purchaser's offer to purchase all of the outstanding AMO Shares as disclosed in the Tender Offer Statement on Schedule TO, as amended or supplemented, initially filed with the Securities and Exchange Commission on January 27, 2009 by Abbott and the Purchaser."},{"field":"security","element":"securityTitle","label":"F3","text":"Includes 6,657,258 AMO Shares tendered through guaranteed delivery procedures."}],"balance_after":58846214,"source":{"system":"sec-edgar","filing":"0001104659-09-012102","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000110465909012102/a4.xml","form_type":"4"}},{"id":646003,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-1 Convertible Preferred Stock","published_at":"2005-02-10T18:57:34.000Z","date":"2005-02-08","kind":"exercise","acquired":false,"shares":400000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares were immediately exercisable.  They had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares were immediately exercisable.  They had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":455235},"source":{"system":"sec-edgar","filing":"0001181431-05-008571","document":"rrd66556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1800/000118143105008571/rrd66556.xml","form_type":"4"}},{"id":646002,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Convertible Preferred Stock","published_at":"2005-02-10T18:57:34.000Z","date":"2005-02-08","kind":"exercise","acquired":false,"shares":1191300,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These shares were immediately exercisable.  They had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These shares were immediately exercisable.  They had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1191300},"source":{"system":"sec-edgar","filing":"0001181431-05-008571","document":"rrd66556.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1800/000118143105008571/rrd66556.xml","form_type":"4"}},{"id":646001,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2005-02-10T18:57:34.000Z","date":"2005-02-08","kind":"exercise","acquired":true,"shares":455235,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Upon the closing of the Issuer's public offering, the Series E-1 Convertible Preferred Stock converted on a 1.138-for-1 basis into Common Stock."}],"balance_after":1646535,"source":{"system":"sec-edgar","filing":"0001181431-05-008571","document":"rrd66556.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1800/000118143105008571/rrd66556.xml","form_type":"4"}},{"id":646000,"issuer":{"id":13934,"kind":"organization","name":"ICAGEN INC","symbol":"ICGN"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2005-02-10T18:57:34.000Z","date":"2005-02-08","kind":"exercise","acquired":true,"shares":1191300,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the closing of the Issuer's public offering, the Series E Convertible Preferred Stock converted on a 1-for-1 basis into Common Stock."}],"balance_after":1191300,"source":{"system":"sec-edgar","filing":"0001181431-05-008571","document":"rrd66556.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000118143105008571/rrd66556.xml","form_type":"4"}},{"id":657113,"issuer":{"id":17647,"kind":"organization","name":"HOSPIRA INC","symbol":"HSP"},"owners":[{"id":2314,"kind":"organization","name":"ABBOTT LABORATORIES","symbol":"ABT","position":1,"cik":"0000001800","reported_name":"ABBOTT LABORATORIES","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2004-05-04T20:38:16.000Z","date":"2004-04-30","kind":"other","acquired":false,"shares":100,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of Common Stock were distributed to holders of Abbott Laboratories common shares in connection with the spin-off of Hospira, Inc. from Abbott Laboratories on April 30, 2004, and were not part of a sale of any kind."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001179110-04-009555","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1800/000117911004009555/edgar.xml","form_type":"4"}}]}